Dr.PathRoch said:

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my…

Thank you — that is the clearest version of this I have read, and I have read a lot of them. I will report back once I have actually tried it.

Clinical perspective, offered as context rather than as advice.

6 month update on cardiovascular risk: down 43 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

Dr.LipidDallas said:

6 month update on cardiovascular risk: down 43 lbs, off blood pressure meds, A1C normalized.

Mine went the same way, slower.

Dr.LipidDallas said:

6 month update on cardiovascular risk: down 43 lbs, off blood pressure meds, A1C normalized.

Dizziness and cardiovascular risk: I was lightheaded for the first 2 weeks. Root cause was a combination of reduced caloric intake and mild dehydration.

Fix: minimum 80-100oz water daily, don't skip meals even if you're not hungry (eat small protein-rich snacks), and stand up slowly from sitting/lying positions. Also check your blood pressure — GLP-1-induced weight loss can make BP meds too strong, requiring dose reduction.

Dr.LipidDallas said:

6 month update on cardiovascular risk: down 43 lbs, off blood pressure meds, A1C normalized.

SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk. In 3,297 T2DM patients with high CV risk: MACE HR 0.74 (95% CI 0.58-0.95, p=0.02)[1].

Notable: the retinopathy signal in SUSTAIN-6 (HR 1.76) was subsequently attributed to rapid A1C reduction in patients with pre-existing retinopathy — not a direct drug effect. This has been confirmed in longer-term follow-up studies.